Growth Hormone Secretagogues

Growth-hormone secretagogues are studied for amplifying the body's own growth-hormone pulse — releasing GH from the pituitary rather than introducing it directly. The research interest is in body composition, recovery, and the age-related decline in GH, using GHRH analogs and GHRPs (growth-hormone releasing peptides).

These are distinct from recombinant human growth hormone itself; they rely on the body's natural feedback loops, which researchers see as a safety advantage. Most of this group is research-grade, with one notable approved exception.

How They Compare

Tesamorelin is FDA-approved specifically for HIV-associated lipodystrophy (excess visceral fat) and is the only member here with current regulatory status. Sermorelin — a short GHRH analog (the active 1–29 fragment) — was approved in the US years ago and later withdrawn as a commercial product, so today it's research-grade too. CJC-1295 (a longer-acting GHRH analog) pairs with the GHRPs — ipamorelin, GHRP-2, and GHRP-6 — which mimic the hunger hormone ghrelin to amplify the GH pulse from the other side of the pathway. Of those, ipamorelin is the most selectively studied, while GHRP-6 is notable for its appetite-stimulating effect.

Published human data on the stacked research compounds is limited — much of the GHRP literature is preclinical, and GHRP-2's clearest human use was as a diagnostic test agent for GH deficiency. The framing stays on what's documented rather than on bodybuilding dosing lore.